DOP2006000184A - Forma farmacéutica con liberación sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph - Google Patents
Forma farmacéutica con liberación sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del phInfo
- Publication number
- DOP2006000184A DOP2006000184A DO2006000184A DO2006000184A DOP2006000184A DO P2006000184 A DOP2006000184 A DO P2006000184A DO 2006000184 A DO2006000184 A DO 2006000184A DO 2006000184 A DO2006000184 A DO 2006000184A DO P2006000184 A DOP2006000184 A DO P2006000184A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- solubility
- depends
- active ingredient
- sustained release
- pharmaceutical form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Formulación farmaceutica sólida para una liberación sostenida independiente del pH de un ingrediente activo, que comprende al menos una capa de uno o mas polimeros insolubles en agua, al menos una capa de uno o mas polimeros con una solubilidad en agua que depende del pH y un nucleo que contiene un ingrediente activo, que tiene una solubilidad en agua que depende marcadamente del pH y comprende al menos un agente osmótico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05090228A EP1749519A1 (de) | 2005-08-05 | 2005-08-05 | Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2006000184A true DOP2006000184A (es) | 2007-05-31 |
Family
ID=35448205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2006000184A DOP2006000184A (es) | 2005-08-05 | 2006-08-04 | Forma farmacéutica con liberación sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP1749519A1 (es) |
JP (1) | JP2009503011A (es) |
CN (1) | CN101257895A (es) |
AR (1) | AR055110A1 (es) |
CA (1) | CA2617280A1 (es) |
DO (1) | DOP2006000184A (es) |
GT (1) | GT200600353A (es) |
PE (1) | PE20070464A1 (es) |
TW (1) | TW200738285A (es) |
UY (1) | UY29728A1 (es) |
WO (1) | WO2007017219A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2007346A1 (en) * | 2006-05-08 | 2008-12-31 | McNeil-PPC, Inc. | Osmotic dosage form |
JP5228359B2 (ja) * | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | 主薬粒子及びその製造方法ならびに口腔内崩壊錠 |
US20130189377A1 (en) * | 2010-07-27 | 2013-07-25 | Norgine Bv | Compositions |
CN103093211B (zh) * | 2013-01-27 | 2015-09-30 | 西安电子科技大学 | 基于深度核信息图像特征的人体运动跟踪方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
SE460945B (sv) * | 1987-01-15 | 1989-12-11 | Lejus Medical Ab | En multipel-unit-dos komposition av furosemid |
MX9605419A (es) * | 1994-05-06 | 1997-12-31 | Pfizer | Formas de dosificacion de liberacion controlada de azitromicina. |
US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
AU2001246861A1 (en) * | 2000-04-10 | 2001-10-23 | Sumitomo Pharmaceuticals Co. Ltd. | Sustained release preparations |
DE10152351B4 (de) * | 2001-10-18 | 2005-09-22 | Schering Ag | Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat |
DE10211289A1 (de) * | 2002-03-14 | 2003-09-25 | Basf Ag | Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität |
-
2005
- 2005-08-05 EP EP05090228A patent/EP1749519A1/de not_active Withdrawn
-
2006
- 2006-08-02 JP JP2008524453A patent/JP2009503011A/ja not_active Ceased
- 2006-08-02 CN CNA2006800288421A patent/CN101257895A/zh active Pending
- 2006-08-02 CA CA002617280A patent/CA2617280A1/en not_active Abandoned
- 2006-08-02 EP EP06776644A patent/EP1926482A2/en not_active Withdrawn
- 2006-08-02 WO PCT/EP2006/007783 patent/WO2007017219A2/en active Application Filing
- 2006-08-04 DO DO2006000184A patent/DOP2006000184A/es unknown
- 2006-08-04 UY UY29728A patent/UY29728A1/es not_active Application Discontinuation
- 2006-08-04 PE PE2006000945A patent/PE20070464A1/es not_active Application Discontinuation
- 2006-08-04 TW TW095128584A patent/TW200738285A/zh unknown
- 2006-08-04 GT GT200600353A patent/GT200600353A/es unknown
- 2006-08-04 AR ARP060103409A patent/AR055110A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1926482A2 (en) | 2008-06-04 |
PE20070464A1 (es) | 2007-06-07 |
JP2009503011A (ja) | 2009-01-29 |
AR055110A1 (es) | 2007-08-08 |
EP1749519A1 (de) | 2007-02-07 |
WO2007017219A3 (en) | 2007-06-28 |
CA2617280A1 (en) | 2007-02-15 |
WO2007017219A2 (en) | 2007-02-15 |
GT200600353A (es) | 2007-03-14 |
TW200738285A (en) | 2007-10-16 |
CN101257895A (zh) | 2008-09-03 |
UY29728A1 (es) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054227A1 (es) | Composicion de principios activos | |
CL2004000837A1 (es) | Pelicula ingerible para adherirse y disolverlo en la cavidad oral, que comprende un polimero soluble en agua, un enmascarador de sucralosa y un agente farmaceuticamente activo. | |
BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
BRPI0714399B8 (pt) | composição farmacêutica líquida oral | |
CL2009002073A1 (es) | Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares. | |
ECSP109852A (es) | Uso de homo y copolímeros para la estabilización de formulaciones de principios activos | |
AR055838A1 (es) | Formulaciones para microproyecciones recubiertas que tienen solubilidad controlada | |
AR048250A1 (es) | Productos de pelicula que tienen propiedades de disgregacion controlada | |
WO2007008752A3 (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
WO2006116718A3 (en) | Pharma-informatics system | |
AR027091A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
AR060234A1 (es) | Gel de suspension espumable | |
PE20160527A1 (es) | Formulaciones de adenovirus mejoradas | |
UY28304A1 (es) | Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad | |
WO2007056205A3 (en) | Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents | |
AR034517A1 (es) | Formulacion farmaceutica | |
ITRM20050393A1 (it) | Sistema di rilascio controllato di sostanze farmacologicamente attive, processo di preparazione e impieghi in campo medico. | |
BRPI0619911A2 (pt) | composto, pró-droga, agente farmacêutico, e, uso do composto | |
PE20150773A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilefrina | |
DOP2006000184A (es) | Forma farmacéutica con liberación sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph | |
AR064104A1 (es) | Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas | |
BRPI0506630A (pt) | composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada | |
AR061655A1 (es) | Composicion de microesferas polimericas degradables | |
WO2007016350A3 (en) | Modified release tablet formulations with enhanced mechanical properties | |
AR053144A1 (es) | Composicion farmaceutica solida que comprende telitromicina |